In-Clinic IV Therapy: Whats the Difference
The broader comparison of injectable vs oral peptides examines the bioavailability differences that make injection the preferred route for most peptide researchers
Mousivand M, Bagherzadeh K, Anfossi L, Javan-Nikkhah M (2022) Key criteria for engineering mycotoxin binding aptamers via computational simulations: Aflatoxin B1 as a case study
Ready to Address Your Hair Loss at the Root
An FDA advisory committee recommended that they be considered for the 503A Bulks List
Preclinical literature reports the use of thymosin beta-4-related peptides in neural, vascular, cutaneous, and cardiovascular models, with histological, biochemical, and molecular analyses aimed at evaluating stress markers, cytoskeletal organization, and tissue response